BTK inhibitor
-
Fenebrutinib: First New Treatment in Over a Decade to Combat Progressive MS Disability
Roche’s investigational drug, fenebrutinib, shows promise in slowing disability progression for primary progressive multiple sclerosis (PPMS). As a BTK inhibitor, it targets inflammation in the central nervous system. This potential breakthrough offers hope for PPMS patients, who have had limited treatment options. The success of fenebrutinib could also validate BTK inhibitors for other neurological conditions, driving further research and investment.
-
.Lilly’s Jaypirca (pirtobrutinib) Achieves Primary Endpoint in Landmark Head‑to‑Head Phase 3 Trial Against Imbruvica (ibrutinib)
words.Eli Lilly’s Phase 3 BRUIN CLL‑314 trial showed pirtobrutinib, a reversible BTK inhibitor, achieved a non‑inferior ORR of 87 % versus 78.5 % for ibrutinib in CLL/SLL patients, meeting its primary endpoint. Early PFS trends favored pirtobrutinib, with a 43 % reduction in progression/death risk overall and 76 % in treatment‑naïve patients. The drug demonstrated a safer profile—lower atrial fibrillation (2.4 % vs. 13.5 %) and hypertension (10.6 % vs. 15.1 %). FDA‑approved after covalent BTK failure, it now seeks frontline indication, potentially reshaping the BTK inhibitor market.
